bioMérieux is a global leader in the field of In-Vitro Diagnostics. Founded in 1897 by Marcel Mérieux, the company has evolved into a family-owned business that has specialized in the development, production, and distribution of diagnostic solutions for over 60 years. These solutions include reagents, devices, software, and services for medical and industrial applications.
The mission of bioMérieux is to protect and improve the health of patients and consumers worldwide. The company is committed to providing high-quality, innovative products and services to identify causes of diseases and sources of contamination, and to meet the needs of laboratories and clinics[2].
bioMérieux is engaged in various social and environmental initiatives. The company emphasizes the importance of global partnerships to promote public health and supports local communities through various programs, such as food collection for the needy or support for educational initiatives[4].
bioMérieux is present in over 160 countries and has an extensive distribution network. The company has offices in 45 countries and is listed on Euronext Paris[2][4]. With a revenue of over 3.1 billion euros in 2020 and more than 90% of sales outside France, bioMérieux demonstrates its strong global orientation[4].
By the end of 2023, bioMérieux employed over 14,600 people worldwide[1]. The company is committed to continuous growth and innovation, as evidenced by the recent acquisition of SpinChip Diagnostics, a Norwegian diagnostics start-up that develops innovative immunoassays[4].
